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γilippos Triposkiadis, George Karayannis, Grigorios Giamouzis, John Skoularigis, George Louridas,
aved Butler
ctivation of the sympathetic nervous system (SNS) provides inotropic support to the failing
eart, increasing stroke volume and stimulating peripheral vasoconstriction to maintain mean
rterial pressure. However, this activation can also accelerate disease progression. Triposkiadis
nd colleagues review the role of SNS activation and pharmacological modification in disease
rogression and reversal. The roles of specific adrenergic receptors (ARs) are reviewed as are
he effects of polymorphisms in these ARs. Finally, the utility of various medications that are
esigned to modulate the SNS, from alpha-blockers to beta-agonists, are reviewed.CLINICAL RESEARCH ROGNOSTICATORS IN ACUTE INFARCTION1763Prognostic Implications of ST-Segment Resolution Differ for PCI and Fibrinolysisaria Sejersten, Nana Valeur, Peer Grande, Torsten Toftegaard Nielsen, Peter Clemmensen,
or the DANAMI-2 Investigators
he prognostic significance of ST-segment resolution may be different for fibrinolysis
ompared with primary percutaneous coronary intervention (pPCI) for patients with acute
yocardial infarction. Sejersten and colleagues reviewed electrocardiograms from the
ANAMI-2 (DANish trial in Acute Myocardial Infarction-2) trial, which randomized
atients to fibrinolysis or pPCI. ST-segment resolution at 90 min was more pronounced after
PCI, but there was no difference at 4 h. In the fibrinolysis group, 30-day and long-term
ortality rates were significantly higher in patients without ST-segment resolution, while
einfarction rates were higher with complete ST-segment resolution. ST-segment resolution
as not associated with the 2 end points in the pPCI group. These results suggest that 4-h
T-segment resolution is an important prognosticator after fibrinolysis but is a less useful
urrogate end point after pPCI.(continued on page A-27)
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EROGNOSTICATORS IN ACUTE INFARCTION1770Cardiac Magnetic Resonance for Post-MI Risk Stratificationebastian Kelle, Stijntje D. Roes, Christoph Klein, Thomas Kokocinski, Albert de Roos, Eckart Fleck,
eroen J. Bax, Eike Nagel
his study by Kelle and colleagues assessed the predictive value of myocardial infarct size
ompared with contractile reserve in medically-treated patients with previous myocardial
nfarction (MI). A total of 177 patients with a history of coronary artery disease and evidence
f scar tissue on late gadolinium-enhanced (LGE) magnetic resonance imaging were enrolled.
eft ventricular (LV) functional parameters at rest and during low-dose dobutamine
timulation were measured. The spatial extent of scar tissue was a stronger predictor of
dverse events than LV ejection fraction and LV volumes. In patients with large scar, 6
yocardial segments, transmurality of infarct was not a predictor of events but the presence of
ontractile reserve was. This study shows that LGE and contractile reserve are useful in
redicting events in medically-treated patients with previous MI.CE INHIBITION AND CORONARY SURGERY1778ACEI Use May Increase Risk of CABGntonio Miceli, Radek Capoun, Carlo Fino, Pradeep Narayan, Alan J. Bryan, Gianni D. Angelini,
assimo Caputo
his study by Miceli and colleagues evaluated the effect of pre-operative angiotensin-
onverting enzyme inhibitor (ACEI) therapy on early clinical outcomes after coronary artery
ypass grafting (CABG). Over 3,000 patients who underwent CABG between 1996 and
008 and who received an ACEI in the 24 h prior to surgery were matched with subjects
ho had not received an ACEI. Pre-operative ACEI therapy was associated with a 2-fold
igher risk of death (1.3% vs. 0.7%). ACEI use was also associated with significantly higher
isks of post-operative renal dysfunction (odds ratio [OR]: 1.36), atrial fibrillation (OR: 1.34),
nd need for inotropic support (OR: 1.22). While a randomized study is needed, these results
uggest that ACEIs should be held for at least 24 h prior to CABG surgery.
ditorial Comment: David S. Bach, p. 1785(continued on page A-36)
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lASCULAR EFFECTS OF NICOTINIC ACID1787Niacin Significantly Reduces Carotid Atherosclerosis in Statin-Treated Patientsustin M. S. Lee, Matthew D. Robson, Ly-Mee Yu, Cheerag C. Shirodaria, Colin Cunnington,
lias Kylintireas, Janet E. Digby, Thomas Bannister, Ashok Handa, Frank Wiesmann, Paul N. Durrington,
eith M. Channon, Stefan Neubauer, Robin P. Choudhury
icotinic acid (NA) raises high-density lipoprotein cholesterol (HDL-C), reduces low-density
ipoprotein cholesterol (LDL-C), and is widely used as an adjunct to statin therapy, but there
s limited evidence that the addition of NA slows or reverses disease progression. Lee and
olleagues performed a double-blind, randomized, placebo-controlled study of 2 g daily
odified-release NA added to statin therapy in patients with low HDL-C (40 mg/dl) and
ther risk factors. The primary end point was the change in carotid artery wall area after 1
ear, as quantified by magnetic resonance imaging; NA increased HDL-C by 23%, decreased
DL-C by 19%, and significantly reduced carotid wall area compared with placebo. There
as a significant inverse correlation between the change in carotid wall area and the change in
DL-C, but no relationship with the change in LDL-C. In statin-treated patients with low
DL-C, high-dose modified-release NA reverses carotid atherosclerosis.ditorial Comment: Farouc A. Jaffer, p. 1795ARDIAC EFFECTS OF SLEEP APNEA1797Increased Risk of Arrhythmias During Periods of Sleep-Disordered Breathingen Monahan, Amy Storfer-Isser, Reena Mehra, Eyal Shahar, Murray Mittleman, Jeff Rottman,
aresh Punjabi, Mark Sanders, Stuart F. Quan, Helaine Resnick, Susan Redline
revious studies have shown an increased risk for atrial fibrillation and nonsustained
entricular tachycardia (NSVT) in subjects with sleep-disordered breathing (SDB), but it is
nclear if respiratory disturbances actually trigger nocturnal arrhythmias. Overnight
olysomnograms from over 2,500 subjects were screened for paroxysmal atrial fibrillation and
SVT. Monahan and colleagues used a case-crossover design to determine whether apneas
nd/or hypopneas preceded these arrhythmias within 90 s by determining if breathing
isturbances also occurred during periods of sinus rhythm without ectopy. The odds of an
rrhythmia following a respiratory disturbance were nearly 18 times higher than the odds of
n arrhythmia during normal breathing. These results support a direct temporal and causal
ink between SDB and arrhythmias.(continued on page A-40)
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EARDIAC EFFECTS OF SLEEP APNEA1805Sleep Apnea Common, Possibly Pathologic, for Patients With HCMackram F. Eleid, Tomas Konecny, Marek Orban, Partho P. Sengupta, Virend K. Somers,
ames M. Parish, Farouk Mookadam, Peter A. Brady, Barbara L. Sullivan, Bijoy K. Khandheria,
teve R. Ommen, A. Jamil Tajik
ynamic left ventricular outflow tract obstruction in patients with hypertrophic
ardiomyopathy (HCM) is potentiated by sympathetic stimulation, and thus could occur
uring the nocturnal hypoxia-induced hyperadrenergic state caused by obstructive sleep apnea
OSA). This study by Eleid and colleagues sought to determine the prevalence of OSA in
atients with HCM. One hundred subjects with HCM were screened with nocturnal
ximetry, and 71% were found to be abnormal with repetitive oxygen desaturations (5
vents/h). This prevalence was higher than an age- and sex-matched control group. HCM
atients with abnormal oximetry were more symptomatic than those without. Further studies
re needed to determine if OSA treatment modifies disease progression in HCM.ditorial Comment: Ian Wilcox, Christopher Semsarian, p. 1810
